Oncobiologics Announces Successful Clinical Trial for IBD Treatment

Oncobiologics Announces Successful Clinical Trial for IBD Treatment
Biopharmaceutical company Oncobiologics, Inc. recently announced that its product ONS-3010, an adalimumab (Humira®) biosimilar candidate, has met the primary endpoints in its first clinical trial. ONS-3010 was developed as a biosimilar of adalimumab, which is an injectable, synthetic (man-made) anti-TNF-alpha monoclonal antibody that binds to TNF (tumor necrosis factor) and blocks inflammation. This drug has been approved in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *